May 2026 Research Update

Across these papers, the main message was consistent: diagnosing autoimmune hemolytic anemia (AIHA) relies on showing that red blood cells are coated by immune proteins, most often using the direct antiglobulin test (DAT, also called the direct Coombs test). Beyond the DAT, blood markers of ongoing red cell breakdown and careful review of the blood smear can add useful supporting evidence and occasionally point to a specific AIHA pattern. [1] [2]

The French adult clinical practice guideline described the DAT as the cornerstone test for AIHA diagnosis and discussed warm and cold forms as different situations that may need different evaluation and management. It also noted that cold-antibody driven AIHA can involve complement (a part of the immune system) contributing to red cell breakdown, which is why some DAT results include complement signals. [1]

One case report described a 61-year-old man whose preoperative lab work led to recognition of mixed AIHA, with DAT positivity showing both IgG (often linked to warm AIHA) and C3 (a complement marker that can be seen in cold-related disease). The authors highlighted that defining the AIHA type required a thorough workup, including antibody testing and evaluation for an underlying cause, even though no clear cause was found in this patient. [3]

A second case report described a 69-year-old woman in whom an unusual microscope pattern, neutrophil-erythrocyte rosettes on the blood smear, triggered targeted testing for AIHA. Follow-up testing with a monospecific DAT confirmed IgG-mediated (warm-type) AIHA, and reticulocytosis plus other hemolysis blood markers supported that red cell breakdown was ongoing. [2]

For patients and caregivers, these papers reinforce that AIHA is usually confirmed using a specific blood test (the DAT/direct Coombs test) rather than symptoms alone, and that additional lab results or blood-smear review may help clarify the type (warm, cold, or mixed). The case reports are single-patient examples, so they mainly illustrate how diagnosis can unfold in real life rather than proving how common these patterns are. What remains uncertain from this set of papers is how often rare smear clues like rosettes occur, and how frequently mixed patterns are missed without specialized testing. [3] [2] [1]

This month, the evidence came from several single-patient case reports rather than larger clinical trials, so results may not apply to everyone. Still, the shared pattern was that when standard treatments did not control autoimmune hemolytic anemia (AIHA), improvement was reported after switching to a treatment aimed at the suspected driver (for example, the spleen, an immune-triggering cancer drug, an underlying immune gene change, or immune problems linked to blood cancer). [4] [5] [6] [7]

In one woman with systemic lupus erythematosus (SLE)-related AIHA that had not responded to multiple prior therapies, spleen removal was followed by a sustained rise in hemoglobin to 135 g/L. The spleen tissue showed signs consistent with ongoing immune activity and red blood cell breakdown (including plasma cell infiltration and complement-related abnormalities), supporting the idea that the spleen can be a key site of disease activity in some people. [4]

In a patient whose AIHA was triggered by pembrolizumab (a checkpoint inhibitor cancer immunotherapy), anemia continued despite corticosteroids and intravenous immunoglobulin (IVIG) until cyclophosphamide plus fluorouracil was added, after which AIHA was controlled. When pembrolizumab was restarted, AIHA returned but then resolved with corticosteroids, and she completed cycles 3 to 8 without further AIHA episodes in this report. [5]

In an 11-month-old infant with recurrent AIHA linked to a TLR7 gain-of-function mutation, many supportive and immune-directed treatments were used during the disease course, and an allogeneic hematopoietic stem cell transplant was followed by hemoglobin stabilization around 100 g/L. The authors also discussed episodes of cytomegalovirus (CMV) infection as a possible factor affecting immune activation in this child. [6]

In a man with chronic lymphocytic leukemia who developed Evans syndrome (AIHA plus immune low platelets) and did not respond to steroids, IVIG, or rituximab, rescue therapy with romiplostim plus zanubrutinib led to platelet recovery within four weeks and a hematologic response lasting more than six months. Thrombocytopenia returned when zanubrutinib was interrupted and improved again when it was restarted, suggesting the immune-modulating drug may have mattered in this single case. [7]

A separate case in a man with Rhupus syndrome (rheumatoid arthritis and SLE overlap) described hematologic remission alongside kidney and lung lining (pleuritis) improvement after escalation to a cyclosporine-based regimen with steroids and background immunosuppressants, though the report did not isolate AIHA outcomes alone. The authors emphasized that a single case cannot prove cause and effect and noted the need to monitor for cyclosporine toxicity. [8]

For patients and caregivers, these reports mainly add background about what has been tried when AIHA does not respond to common first treatments, and they highlight that the best next step may depend on the situation (such as lupus-related disease, cancer-immunotherapy-related AIHA, rare genetic immune disease, or Evans syndrome with a blood cancer). Because each paper describes only one person, it is still uncertain how often these approaches work, who is most likely to benefit, and what the risks are across a broader group.

Across this paper, the main message is that an infection can sometimes trigger autoimmune hemolytic anemia (AIHA) at the same time as inflammation in other organs, and care may need to balance risks when more than one system is involved. The evidence here is from a single case report, so it cannot show how common this is or predict what will happen for most people. [9]

In an 18-year-old woman with Epstein-Barr virus (EBV) infectious mononucleosis, doctors diagnosed warm AIHA based on a positive direct antiglobulin test (IgG positive, C3d negative) alongside lab signs of red blood cell breakdown and a hemoglobin drop from 11.2 to 8.9 g/dL. At the same time, she had cholestatic hepatitis with yellowing of the skin and eyes and a high direct bilirubin (direct 8.3 mg/dL). [9]

Imaging was used to help rule out a blockage of the bile ducts as a cause of jaundice, and the patient did not progress to liver failure. Because of concern about liver injury, prednisone was stopped after two doses, and she improved with supportive care while her EBV viral load decreased from 18,400 copies/mL at admission to 3,100 copies/mL at discharge. [9]

For patients and caregivers, this report is most relevant as background that AIHA can sometimes appear during a viral illness and may occur alongside liver inflammation, which can affect how clinicians think about monitoring and risk. Because it describes only one person, it does not tell whether this approach applies broadly or which people with EBV are most likely to develop AIHA or hepatitis. It does show that doctors may use blood tests and imaging to separate red blood cell breakdown from other causes of jaundice, and that recovery can occur without progression to liver failure in at least one reported case. [9]

This month, the clearest pattern was that autoimmune hemolytic anemia (AIHA) can happen as part of a broader condition rather than on its own, including systemic autoimmune disease, inherited immune system problems, and certain lymphomas and leukemias. The evidence ranges from single-patient case reports to a large registry study, so the strength of conclusions varies. Overall, these papers highlight that the bigger health context can shape what symptoms appear and how the illness unfolds over time. [10] [11] [12] [13] [14]

In one adult case, warm AIHA was part of late-onset systemic lupus erythematosus (an autoimmune disease) and appeared at the same time as life-threatening fluid buildup around the heart that caused cardiac tamponade. The patient improved after the fluid was drained and after immune-suppressing treatments, and the authors noted a few similar adult cases reported previously. This shows that, in some people, AIHA may appear together with serious inflammation outside the blood, including around the heart. [10]

Two case reports connected AIHA-type conditions with blood cancers across time. A 78-year-old woman had cold agglutinin syndrome (a cold-triggered form of immune hemolysis) that came before a later diagnosis of acute myeloid leukemia; despite improvement in a blood test for the cold antibody after rituximab, her anemia worsened and leukemia was found, and she died after two cycles of leukemia-directed therapy. In a separate report, a man previously treated for non-Hodgkin lymphoma developed delayed warm AIHA years after remission, needed transfusions, and improved after rituximab, with imaging raising concern for ongoing lymphoid activity even without a confirming biopsy. [11] [12]

A population-based study in England focused on angioimmunoblastic T-cell lymphoma and reported that AIHA was recorded in 5.6% of 993 patients, showing AIHA is a recognized complication in this lymphoma at a measurable rate. The same study also reported that some people later developed another lymphoma type (a B-cell lymphoma or Hodgkin lymphoma), reinforcing that immune and blood-cancer diagnoses can overlap over time in this setting. These registry results provide broader context beyond individual case reports, but they do not explain why AIHA occurs in specific patients. [13]

In children, a small case series described LRBA deficiency, a rare inherited immune disorder, where autoimmune cytopenias (low blood counts caused by autoimmunity) were common and could include AIHA with spleen enlargement. The children had very different symptoms beyond anemia, including infections, gut inflammation, eye inflammation, diabetes, and lung involvement in one case, and some improved clinically with abatacept. This illustrates that, in some families, AIHA may be one part of a larger immune system condition rather than the only problem. [14]

For patients and caregivers, these papers mainly add background on situations where AIHA can be linked to another diagnosis: systemic lupus (including rare cases with fluid around the heart), certain lymphomas, rare immune gene disorders in children, and in one reported case, leukemia discovered after cold agglutinin syndrome. Most of the evidence here comes from individual cases, so it cannot predict what will happen for any one person, but it can help explain why clinicians sometimes look for an underlying immune condition or blood cancer when AIHA appears or changes. What remains uncertain is how often these links occur outside of the specific lymphoma registry study, and which symptoms or lab changes best identify who has an underlying condition.

Across these papers, autoimmune hemolytic anemia (AIHA) and related immune blood count problems were described in three settings: a specific antibiotic exposure, a time-linked event after vaccination in a person with past immune cytopenias, and a delayed complication after kidney transplant induction therapy. The evidence is mainly from case reports plus one moderate-strength, single-center retrospective study, so the true frequency and individual risk remain uncertain. Overall, the reports highlight that timing (including delayed onset or relapse) and the specific trigger can matter for how these events show up and how they resolve. [15] [16] [17]

In one patient, severe hemolysis occurred after re-exposure to vancomycin, and the direct antiglobulin test became positive, with gradual hemoglobin recovery after vancomycin was stopped and without using immune-suppressing medicines. The report also noted coagulation test changes and a high platelet count during the episode, alongside symptoms like chills, palpitations, and restlessness. Because this is a single case with a brief literature review, it cannot show how often vancomycin causes this or predict who is at risk. [15]

Another single-patient report described a 68-year-old man with a history of immune thrombocytopenia (low platelets) and AIHA who had a severe relapse of thrombocytopenia shortly after COVID-19 vaccination; testing did not show active hemolysis during that relapse. The main clinical issue was bleeding risk from extremely low platelets, and counts improved after multiple therapies, with no brain bleeding seen on a head scan. The authors emphasized that a time link does not prove the vaccine caused the relapse. [16]

In a retrospective study of 40 kidney transplant recipients who developed autoimmune cytopenias after alemtuzumab induction, AIHA occurred in 7 people and Evans syndrome (more than one immune cytopenia) in 5, with two peaks of onset around 18 and 36 months after induction. First treatments worked similarly to what is seen in people with primary (non-transplant) forms, but about two-thirds needed second-line treatment; rituximab and thrombopoietin receptor agonists were reported as helpful for immune thrombocytopenia in this setting. Infections and blood clot or cardiovascular complications were common in this transplant group, showing the added safety complexity when autoimmune cytopenias happen alongside transplant-related immune suppression and other risks. [17]

For patients and caregivers, this set of papers mainly provides context about when AIHA or related immune blood count problems have been reported in real-world situations: after re-starting a specific antibiotic, after a vaccination in someone with prior immune cytopenias, and long after kidney transplant induction therapy. The transplant study suggests these complications can appear months to years later and may require more than first-round treatment, while also occurring in a setting where infections and clots are already important concerns. What remains uncertain is how common these events are and which personal factors increase risk, because two papers describe single individuals and the transplant paper comes from one center. [15] [16] [17]

Across these papers, complications around immune suppression and complex medical situations stood out more than day-to-day symptom control. A multicenter study showed infections were not rare after rituximab in autoimmune blood disorders, and the case reports illustrated how fast complications can escalate in settings like catastrophic clotting syndromes or major surgery. Overall, the evidence includes one moderate-strength retrospective study and two single-patient reports, so the details from the cases may not apply to most people. [18] [19] [20]

In a retrospective Italian cohort of 285 people treated with rituximab (including autoimmune hemolytic anemia and related autoimmune blood conditions), 65 out of 285 patients had an infectious event. Infection-related death occurred in 9 patients. The 180-day infection incidence was higher in autoimmune blood disorders than in indolent non-Hodgkin lymphoma (13.7% vs 9.4%). [18]

In the same study, higher infection risk was linked to developing low antibody (IgG) levels after rituximab and to use of antimicrobial prophylaxis (likely reflecting that higher-risk patients were selected for prophylaxis). The authors highlighted monitoring antibody levels and careful use of antibiotics as part of reducing infection burden in routine care. [18]

One case report described a 54-year-old woman who presented with autoimmune hemolytic anemia and was later diagnosed with catastrophic antiphospholipid syndrome, a rare condition with widespread clotting. Despite intensive treatment including blood thinners, high-dose steroids, plasma exchange, and intravenous immunoglobulin, she developed severe infections and died; autopsy confirmed multi-organ thrombosis and disseminated infection. The report also noted that early imaging did not capture all clotting, underscoring diagnostic difficulty in this situation. [19]

A second case report focused on a different special situation: major bone surgery with microvascular reconstruction in a 21-year-old woman with Evans syndrome (autoimmune hemolytic anemia plus immune thrombocytopenia) and common variable immunodeficiency. The team described coordinated perioperative planning, including temporary holds of some immune medicines, continuing intravenous immunoglobulin, and clot prevention measures; the patient had bone healing at 4 months and no reported hematoma, thrombosis, or infection. As a single case, it shows what was feasible for one person rather than a general expected outcome. [20]

For patients and caregivers, this set of papers mainly adds context about complications that can occur in higher-risk circumstances: infections after rituximab in real-world care, rare but severe clotting syndromes that can present alongside autoimmune hemolytic anemia, and the added planning that may be needed around major surgery in people with overlapping immune problems. The strongest data here are about infection frequency after rituximab in a mixed group of autoimmune blood disorders, while the two case reports are most useful as background examples of what can happen in unusual, complex scenarios. Important uncertainties remain, including which individual factors best predict infection risk and how often rare clotting syndromes overlap with autoimmune hemolytic anemia in broader populations. [18] [19] [20]